Chronic Kidney Disease Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to give their informed consent to participate
• People aged 18 years or older
• People who fall into one of these three groups: those who have been on regular, stable haemodialysis (kidney-filtering treatment using a machine) for at least three months; those who have recently been prescribed haemodialysis for the first time; or those currently on peritoneal dialysis (a different type of kidney filtering) who need to switch to haemodialysis
• People whose dialysis access point (such as a fistula or catheter) can deliver blood flow at a sufficient rate for the treatment
• People who understand what the study involves and what will be expected of them
• People who are willing and able to follow the study requirements, including attending all required treatment sessions and check-ups

Who may not be able to join:

• People whose body weight when fully drained of excess fluid is 60 kg or under, or 110 kg or over
• People with a recorded history of regularly missing scheduled dialysis sessions or clinic appointments
• People who are already scheduled to receive a living kidney transplant within the next two months, who plan to switch to peritoneal dialysis within the next two months, or who need a specific type of dialysis called single needle dialysis
• People with unstable levels of salts or acids in their blood, as judged by the treating doctor
• People who have had a major surgery or a serious heart event within the three months before the screening visit
• People who have had repeated episodes of blood pressure that is too low or too high in the 30 days before screening
• People with an active or ongoing infection, as judged by the treating doctor
• People with a known diagnosis of Hepatitis B, Hepatitis C, or HIV
• People with documented blood clotting disorders, an active or increased risk of bleeding, or who cannot tolerate heparin (a common blood-thinning medication used during dialysis)
• People who are currently taking part in, or have taken part in, another interventional clinical trial within the four weeks before screening
• People with other health conditions that the treating doctor believes may conflict with the study's aims or procedures
• People who are pregnant or breastfeeding, or people who are capable of becoming pregnant and who are unwilling to use a medically accepted form of contraception
• People with an active cancer diagnosis where life expectancy is estimated to be less than six months, as judged by the treating doctor
• People whose haemoglobin (a measure of red blood cells) was below 9 g/dL in the 30 days before screening
• People who have had significant episodes of low blood pressure during dialysis sessions in the 30 days before screening
• People who experienced shock (a serious drop in blood flow) within the 30 days before screening
• People who have had active seizures within the six months before screening
• People with a history of a condition where red blood cells are destroyed abnormally (haemolytic anaemia) or low platelet counts (thrombocytopenia)
• People with recent problems with their dialysis access point, including reversed line connections, catheter replacement, multiple uses of a clot-clearing medication, or a procedure to remove a clot — all within the 30 days before screening
• People with a documented history of moderate-to-severe heart failure (classified as NYHA Class III or IV) or severely reduced heart pumping function, as judged by the treating doctor
• People whose fluid overload is caused by fluid build-up in the abdomen due to severe liver disease (liver cirrhosis)
• People with a serious, life-threatening disease affecting the joints or immune system (rheumatologic disease)

Important: Always verify eligibility with the trial site directly before applying.